Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 107 for:    "Vascular Hemostatic Disease" | "Doxorubicin"

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01177683
Recruitment Status : Terminated (Lack of accrual)
First Posted : August 9, 2010
Last Update Posted : July 16, 2018
Sponsor:
Collaborators:
Hoosier Cancer Research Network
Cephalon
Information provided by (Responsible Party):
Sherif Farag, MB, BS, Hoosier Cancer Research Network

Brief Summary:
This is an open label phase I/II trial to determine the safety and the biologic activity of the bendamustine, bortezomib and pegylated liposomal doxorubicin combination.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Bendamustine Drug: Doxorubicin Drug: Bortezomib Drug: Filgrastim Phase 1 Phase 2

Detailed Description:

Phase I component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV over 1 hour, Day 4 Bendamustine escalating cohorts IV over 1 hour, Days 1 and 4 1 Cycle = 28 days

Phase II component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV over 1 hour, Day 4 Bendamustine at MTD IV over 1 hour, Days 1 and 4 Filgrastim (if defined in MTD) 5 µg/kg/day SC, Starting day 6 until neutrophil recovery to ANC >1000

1 Cycle = 28 days; Patients will continue treatment for a total of up to 8 cycles.

ECOG Performance Status: 0-2

Hematopoietic:

  • Absolute neutrophil count (ANC) ≥ 1.2 x K/mm3
  • Platelets ≥ 75 x K/mm3

Hepatic:

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
  • AST ≤ 2.5 x ULN
  • ALT ≤ 2.5 x ULN

Renal:

  • Serum creatinine < 3.0 mg/dL

Cardiovascular:

  • LVEF >45% corrected by MUGA scan or echocardiogram.
  • No unstable angina pectoris or recent myocardial infarction (within 6 months)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
Study Start Date : July 2010
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017


Arm Intervention/treatment
Experimental: Arm 1
Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
Drug: Bendamustine

Phase I component:

Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4


Drug: Doxorubicin

Phase I and II components:

Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4


Drug: Bortezomib

Phase I and II components:

Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11


Drug: Bendamustine

Phase II component:

Bendamustine at at MTD IV over 1 hour, Days 1 and 4


Drug: Filgrastim

Phase II component:

Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000





Primary Outcome Measures :
  1. Assessing Patient Response to Bendamustine - Phase I by assessing patient adverse events [ Time Frame: 6 months ]
    Determine the maximum tolerated dose of bendamustine in association with bortezomib and pegylated liposomal doxorubicin in patients with relapsed or refractory Multiple Myeloma.

  2. Overall Response Rate of Treatment Regimen - Phase II by assessing patient response rates [ Time Frame: 8 months ]
    Assess the overall response rate (CR+PR) of bendamustine in association with bortezomib and pegylated liposomal doxorubicin in patients with relapsed or refractory Multiple Myeloma.


Secondary Outcome Measures :
  1. Toxicity of Treatment Regimen - Phase I and II by assessing patient adverse events [ Time Frame: 6 months ]
    Describe the toxicity of the combination of bendamustine with bortezomib and pegylated liposomal doxorubicin.

  2. Evaluation of Survival - Phase II by assessing patient survival times [ Time Frame: 8 months ]
    Evaluate the time to progression, overall survival, progression free survival, and duration of response of Multiple Myeloma patients treated with bendamustine, bortezomib and pegylated liposomal doxorubicin.

  3. Bendamustine Pharmacokinetics - Phase II by evaluating patient samples [ Time Frame: 8 months ]
    Correlate bendamustine pharmacokinetics parameters (Cmax, t1/2, and AUC) at cycle 1 (and cycle 2) with patients' responses and correlate the DNA damage/repair at day 1 of cycle 1 and day 4 of cycle 2 with patients' responses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease.
  • Must have a detectable serum or urine M-Protein by protein electrophoresis that is at least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light chain level >100 mg/l for the involved free light chain.
  • Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.
  • Must be willing to provide correlative blood samples.

Exclusion Criteria:

  • Must not have received an excessive cumulative dose of anthracycline
  • No ≥ grade 2 peripheral neuropathy.
  • No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.
  • No autologous stem cell transplant within 6 months prior to registration for protocol therapy
  • No prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.
  • No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.
  • No known central nervous system involvement by myeloma.
  • No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements.
  • No patients known to be positive for HIV, or active Hepatitis A, B, or C.
  • No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01177683


Locations
Layout table for location information
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
IU Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States, 46219
Community Regional Cancer Center
Indianapolis, Indiana, United States, 46256
IU Health Arnett Cancer Center
Lafayette, Indiana, United States, 47904
United States, Michigan
Metro Health Cancer Care
Wyoming, Michigan, United States, 49519
United States, Ohio
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Sherif Farag, MB, BS
Hoosier Cancer Research Network
Cephalon
Investigators
Layout table for investigator information
Study Chair: Sherif Farag, M.B., B.S. Hoosier Cancer Research Network

Additional Information:
Layout table for additonal information
Responsible Party: Sherif Farag, MB, BS, Sponsor-Investigator, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier: NCT01177683     History of Changes
Other Study ID Numbers: MM08-141
First Posted: August 9, 2010    Key Record Dates
Last Update Posted: July 16, 2018
Last Verified: July 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemostatic Disorders
Doxorubicin
Liposomal doxorubicin
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bortezomib
Bendamustine Hydrochloride
Lenograstim
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents